iNNOVATE™: LIVING LONGER WITHOUT PROGRESSION, IMBRUVICA® + RITUXIMAB VS RITUXIMAB

iNNOVATE™ Study Design1

iNNOVATE™ was a randomized, double-blind, placebo-controlled, phase 3 study of treatment-naïve and previously-treated patients (n=150).
 

Superior PFS with Up to 5 Years of Follow-up1

Primary Endpoint: Progression-Free Survival (PFS)1-3

  • Long-term data from final analysis, with overall follow-up of 63 months; median follow-up was 50 months1,3

*P value is from the stratified log-rank test.

CI=confidence interval, HR=hazard ratio, NE=not evaluable, PFS=progression-free survival, WM=Waldenström’s Macroglobulinemia.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2Data on file. 3Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52-62. doi:10.1200/JCO.21.00838